查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2108356

間質幹細胞市場分析及預測（至2035年）：類型、產品、服務、技術、應用、過程、最終用戶、模式、階段

Mesenchymal Stem Cells Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球間間質幹細胞（MSC）市場預計將從2025年的42億美元成長到2035年的115億美元，CAGR為10.6%。間質幹細胞市場正經歷穩定成長，這主要得益於臨床研究的增加、再生醫學投資的加大以及細胞療法的商業化。根據美國國家衛生實驗室（ClinicalTrials.gov）的資料顯示，目前在整形外科、自體免疫疾病、心血管疾病和發炎性疾病領域，數百項進行且已完成的間質幹細胞臨床試驗進行中。美國食品藥物管理局（FDA）持續加強對再生醫學產品的法律規範，而歐洲藥品管理局（EMA）則透過專門的監管管道支持先進的治療藥物。研究經費的增加、符合GMP標準的生產設施的擴建以及生物技術公司與研究機構之間合作的加強，都將繼續提升市場的長期成長前景。

服務部門為間質幹細胞的保存、檢驗和最佳化提供專業的實驗室解決方案，貫穿整個研發流程。細胞庫確保標準化的間質幹細胞樣本在受控的低溫條件下長期保存，保證臨床一致性和符合監管要求。細胞表徵採用分子和細胞學檢測方法，檢驗細胞的鑑定、存活率、純度和功能性生物標記。同時，細胞分化服務評估間質幹細胞分化為成骨細胞、成軟骨細胞和成脂細胞的能力。隨著再生醫學、臨床試驗和標準化生產領域投資的不斷增加，生技和製藥業對間質幹細胞外包服務的需求日益成長，這些服務能夠提高可重複性、品質保證和商業化準備度。

市場區隔
類型 同種異體、自體、其他
產品 細胞株、培養基、試劑、設備、其他
服務 細胞庫建置、細胞表徵、細胞處理、其他
技術 細胞增殖、細胞分離、冷凍保存、其他
用途 藥物研發、創傷治療、心血管疾病、整形外科疾病、神經病變、免疫系統疾病、其他
過程 體外分化、體內分化、其他
最終用戶 醫院、研究機構、生物製藥公司、診所、其他
模式 侵入性、非侵入性、其他
階段 臨床前、臨床階段、商業化、其他

間質幹細胞（MSC）市場的技術解決方案著重可擴展的生產、高效的細胞收集以及高品質的幹細胞儲存，以滿足研究和治療應用的需求。細胞增殖技術利用先進的反應器、最佳化的培養基和自動化系統，在維持細胞生物學特性的同時，生產出臨床可用數量的細胞。細胞分離技術採用磁分離、密度梯度離心和微流體平台，以提高細胞純度和回收率。冷凍保存技術透過控制冷凍速率和最佳化的儲存方案，維持細胞的長期活性。持續的創新、自動化以及符合GMP規範的生產流程，提高了產能，並推動了基於MSC療法的更廣泛商業化應用。

區域概覽

北美憑藉其成熟的生物技術生態系統、先進的臨床研究基礎設施以及公共和私人部門對再生醫學的大量投資，在間質幹細胞市場保持主導地位。美國透過強大的藥物創新能力、廣泛的幹細胞研究計畫以及符合GMP標準的生產設施，做出了重要貢獻。支持性的法律規範、生物技術公司與學術機構之間日益密切的合作以及細胞療法商業化的進展，鞏固了該地區的主導地位。臨床試驗的持續擴展、技術創新以及完善的醫療保健基礎設施，維持了對間質幹細胞產品和專業研究服務的強勁需求。

亞太地區透過不斷提昇生物技術能力、加大對醫療保健領域的投資以及政府對再生醫學研究的支持，持續鞏固其市場地位。日本、中國、韓國和澳洲等國家投資建設幹細胞生產設施、轉化研究中心和先進的臨床計畫。有利的監管改革、不斷擴大的醫藥外包業務以及慢性病盛行率的上升，正推動間質幹細胞（MSC）技術的廣泛應用。隨著國際合作的加強、基礎設施的改善以及成本效益高的生產能力的提升，預計該地區在研究、臨床應用和商業化生產領域將持續成長。

主要趨勢和促進因素

新一代細胞製造技術革新間質幹細胞治療

間質幹細胞（MSC）市場正迅速採用自動化、封閉式生產平台，目的是提高規模化生產、可重複性和合規性。人工智慧（AI）驅動的細胞分析、先進的反應器技術、無血清培養和數位化品質監控提高生產效率，同時降低污染風險。這些創新技術支持商業規模生產，縮短治療研發週期，並提高臨床間質幹細胞產品的整體一致性。

再生醫學研發管線的擴展加速間質幹細胞市場的成長。

對再生醫學和細胞療法日益成長的需求正推動間質幹細胞（MSC）市場顯著擴張。整形外科、自體免疫疾病、心血管疾病和發炎性疾病的盛行率不斷上升，加速了MSC治療的臨床研究。生技公司、製藥企業、研究機構和政府機構加大投資，促進了產品開發、臨床檢驗和生產能力的提升，在全球幹細胞價值鏈中創造了持續的需求。

目錄

第1章 執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機會
  • 市場限制因素
  • 年複合成長率分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 同種異體
    • 自體
    • 其他
  • 市場規模及預測：依產品分類
    • 細胞株
    • 培養基
    • 試劑
    • 裝置
    • 其他
  • 市場規模及預測：依應用領域分類
    • 藥物研發
    • 創傷治療
    • 心血管疾病
    • 整形外科疾病
    • 神經病變
    • 免疫系統疾病
    • 其他
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 研究機構
    • 生物製藥公司
    • 診所
    • 其他
  • 市場規模及預測：依技術分類
    • 細胞增殖
    • 細胞分離
    • 冷凍保存
    • 其他
  • 市場規模及預測：依製程分類
    • 體外分化
    • 體內分化
    • 其他
  • 市場規模及預測：依服務分類
    • 細胞庫
    • 細胞表徵
    • 細胞處理
    • 其他
  • 市場規模及預測：依階段分類
    • 臨床前
    • 臨床階段
    • 商業
    • 其他
  • 市場規模及預測：依模式
    • 侵入性
    • 非侵入性
    • 其他

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲國家
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太國家
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲國家

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 定價和成本利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要公司的策略

第8章 公司簡介

  • Lonza Group
  • Thermo Fisher Scientific
  • Cytori Therapeutics
  • Osiris Therapeutics
  • Mesoblast
  • Athersys
  • Pluristem Therapeutics
  • Stemcell Technologies
  • Fate Therapeutics
  • BrainStorm Cell Therapeutics
  • Cynata Therapeutics
  • BioCardia
  • Vericel Corporation
  • Anterogen
  • Celltex Therapeutics
  • Stempeutics Research
  • Promethera Biosciences
  • ReNeuron Group
  • BioRestorative Therapies
  • DiscGenics

第9章 關於我們

簡介目錄
Product Code: GIS25758

The global Mesenchymal Stem Cells Market is projected to grow from $4.2 billion in 2025 to $11.5 billion by 2035, at a compound annual growth rate (CAGR) of 10.6%. The Mesenchymal Stem Cells market is experiencing steady expansion, supported by increasing clinical research, regenerative medicine investments, and cell therapy commercialization. According to the U.S. National Institutes of Health (ClinicalTrials.gov), hundreds of active and completed clinical studies involve mesenchymal stem cells across orthopedic, autoimmune, cardiovascular, and inflammatory disorders. The U.S. Food and Drug Administration (FDA) continues to strengthen regulatory oversight for regenerative medicine products, while the European Medicines Agency (EMA) supports advanced therapy medicinal products through dedicated regulatory pathways. Rising research funding, expanding GMP manufacturing facilities, and increasing collaborations between biotechnology companies and research institutions continue to strengthen long-term market growth prospects.

The services segment encompasses specialized laboratory solutions that preserve, validate, and optimize mesenchymal stem cells throughout research and therapeutic development. Cell banking ensures long-term storage of standardized MSC samples under controlled cryogenic conditions, supporting clinical consistency and regulatory compliance. Cell characterization verifies identity, viability, purity, and functional biomarkers using molecular and cellular assays, while cell differentiation services assess the capability of MSCs to develop into osteogenic, chondrogenic, and adipogenic lineages. Growing investments in regenerative medicine, clinical trials, and standardized manufacturing are expanding demand for outsourced MSC services that improve reproducibility, quality assurance, and commercialization readiness across biotechnology and pharmaceutical industries.

Market Segmentation
TypeAllogeneic, Autologous, Others
ProductCell Lines, Culture Media, Reagents, Instruments, Others
ServicesCell Banking, Cell Characterization, Cell Processing, Others
TechnologyCell Expansion, Cell Isolation, Cryopreservation, Others
ApplicationDrug Development, Injury Treatment, Cardiovascular Diseases, Orthopedic Disorders, Neurological Disorders, Immunological Disorders, Others
ProcessIn Vitro Differentiation, In Vivo Differentiation, Others
End UserHospitals, Research Institutes, Biopharmaceutical Companies, Clinics, Others
ModeInvasive, Non-invasive, Others
StagePre-clinical, Clinical, Commercial, Others

Technology solutions in the MSC market focus on scalable manufacturing, efficient harvesting, and preservation of high-quality stem cells for research and therapeutic applications. Cell expansion technologies utilize advanced bioreactors, optimized culture media, and automated systems to produce clinically relevant cell quantities while maintaining biological characteristics. Cell isolation technologies employ magnetic separation, density-gradient centrifugation, and microfluidic platforms to improve purity and recovery efficiency. Cryopreservation technologies maintain long-term cell viability through controlled-rate freezing and optimized storage protocols. Continuous technological innovation, automation, and GMP-compliant manufacturing processes are strengthening production capacity and supporting broader commercialization of MSC-based therapies.

Geographical Overview

North America maintains a leading position in the Mesenchymal Stem Cells market owing to its mature biotechnology ecosystem, advanced clinical research infrastructure, and substantial public and private investments in regenerative medicine. The United States contributes significantly through strong pharmaceutical innovation, extensive stem cell research programs, and widespread adoption of GMP-compliant manufacturing facilities. Supportive regulatory frameworks, growing collaboration between biotechnology firms and academic institutions, and increasing commercialization of cell-based therapies reinforce regional leadership. Continuous expansion of clinical trials, technological innovation, and established healthcare infrastructure sustain robust demand for MSC products and specialized research services.

Asia-Pacific continues to strengthen its position through expanding biotechnology capabilities, increasing healthcare investments, and supportive government initiatives promoting regenerative medicine research. Countries including Japan, China, South Korea, and Australia are investing in stem cell manufacturing facilities, translational research centers, and advanced clinical programs. Favorable regulatory reforms, growing pharmaceutical outsourcing activities, and rising prevalence of chronic diseases are encouraging broader adoption of MSC technologies. Increasing international collaborations, infrastructure development, and cost-effective manufacturing capabilities position the region for sustained expansion across research, clinical applications, and commercial production.

Key Trends and Drivers

Next-Generation Cell Manufacturing Revolutionizing MSC Therapies:

The MSC market is witnessing rapid adoption of automated and closed-system manufacturing platforms designed to improve scalability, reproducibility, and regulatory compliance. Artificial intelligence-assisted cell analytics, advanced bioreactor technologies, serum-free culture media, and digital quality monitoring are enhancing manufacturing efficiency while reducing contamination risks. These innovations support commercial-scale production, accelerate therapy development timelines, and improve consistency across clinical-grade mesenchymal stem cell products.

Expanding Regenerative Medicine Pipeline Accelerates MSC Market Growth:

Growing demand for regenerative medicine and cell-based therapies is driving significant expansion of the Mesenchymal Stem Cells (MSC) market. Increasing prevalence of orthopedic disorders, autoimmune diseases, cardiovascular conditions, and inflammatory diseases has accelerated clinical research into MSC therapeutics. Rising investments from biotechnology companies, pharmaceutical manufacturers, research institutes, and government agencies are supporting product development, clinical validation, and manufacturing capacity, creating sustained demand across the global stem cell value chain.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by End User
  • 2.5 Key Market Highlights by Technology
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by Services
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Allogeneic
    • 4.1.2 Autologous
    • 4.1.3 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cell Lines
    • 4.2.2 Culture Media
    • 4.2.3 Reagents
    • 4.2.4 Instruments
    • 4.2.5 Others
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Drug Development
    • 4.3.2 Injury Treatment
    • 4.3.3 Cardiovascular Diseases
    • 4.3.4 Orthopedic Disorders
    • 4.3.5 Neurological Disorders
    • 4.3.6 Immunological Disorders
    • 4.3.7 Others
  • 4.4 Market Size & Forecast by End User (2020-2035)
    • 4.4.1 Hospitals
    • 4.4.2 Research Institutes
    • 4.4.3 Biopharmaceutical Companies
    • 4.4.4 Clinics
    • 4.4.5 Others
  • 4.5 Market Size & Forecast by Technology (2020-2035)
    • 4.5.1 Cell Expansion
    • 4.5.2 Cell Isolation
    • 4.5.3 Cryopreservation
    • 4.5.4 Others
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 In Vitro Differentiation
    • 4.6.2 In Vivo Differentiation
    • 4.6.3 Others
  • 4.7 Market Size & Forecast by Services (2020-2035)
    • 4.7.1 Cell Banking
    • 4.7.2 Cell Characterization
    • 4.7.3 Cell Processing
    • 4.7.4 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Pre-clinical
    • 4.8.2 Clinical
    • 4.8.3 Commercial
    • 4.8.4 Others
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 Invasive
    • 4.9.2 Non-invasive
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 End User
      • 5.2.1.5 Technology
      • 5.2.1.6 Process
      • 5.2.1.7 Services
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 End User
      • 5.2.2.5 Technology
      • 5.2.2.6 Process
      • 5.2.2.7 Services
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 End User
      • 5.2.3.5 Technology
      • 5.2.3.6 Process
      • 5.2.3.7 Services
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 End User
      • 5.3.1.5 Technology
      • 5.3.1.6 Process
      • 5.3.1.7 Services
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 End User
      • 5.3.2.5 Technology
      • 5.3.2.6 Process
      • 5.3.2.7 Services
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 End User
      • 5.3.3.5 Technology
      • 5.3.3.6 Process
      • 5.3.3.7 Services
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 End User
      • 5.4.1.5 Technology
      • 5.4.1.6 Process
      • 5.4.1.7 Services
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 End User
      • 5.4.2.5 Technology
      • 5.4.2.6 Process
      • 5.4.2.7 Services
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 End User
      • 5.4.3.5 Technology
      • 5.4.3.6 Process
      • 5.4.3.7 Services
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 End User
      • 5.4.4.5 Technology
      • 5.4.4.6 Process
      • 5.4.4.7 Services
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 End User
      • 5.4.5.5 Technology
      • 5.4.5.6 Process
      • 5.4.5.7 Services
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 End User
      • 5.4.6.5 Technology
      • 5.4.6.6 Process
      • 5.4.6.7 Services
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 End User
      • 5.4.7.5 Technology
      • 5.4.7.6 Process
      • 5.4.7.7 Services
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 End User
      • 5.5.1.5 Technology
      • 5.5.1.6 Process
      • 5.5.1.7 Services
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 End User
      • 5.5.2.5 Technology
      • 5.5.2.6 Process
      • 5.5.2.7 Services
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 End User
      • 5.5.3.5 Technology
      • 5.5.3.6 Process
      • 5.5.3.7 Services
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 End User
      • 5.5.4.5 Technology
      • 5.5.4.6 Process
      • 5.5.4.7 Services
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 End User
      • 5.5.5.5 Technology
      • 5.5.5.6 Process
      • 5.5.5.7 Services
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 End User
      • 5.5.6.5 Technology
      • 5.5.6.6 Process
      • 5.5.6.7 Services
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 End User
      • 5.6.1.5 Technology
      • 5.6.1.6 Process
      • 5.6.1.7 Services
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 End User
      • 5.6.2.5 Technology
      • 5.6.2.6 Process
      • 5.6.2.7 Services
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 End User
      • 5.6.3.5 Technology
      • 5.6.3.6 Process
      • 5.6.3.7 Services
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 End User
      • 5.6.4.5 Technology
      • 5.6.4.6 Process
      • 5.6.4.7 Services
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 End User
      • 5.6.5.5 Technology
      • 5.6.5.6 Process
      • 5.6.5.7 Services
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Lonza Group
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Thermo Fisher Scientific
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Cytori Therapeutics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Osiris Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Mesoblast
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Athersys
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Pluristem Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Stemcell Technologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Fate Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 BrainStorm Cell Therapeutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Cynata Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 BioCardia
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Vericel Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Anterogen
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Celltex Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Stempeutics Research
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Promethera Biosciences
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 ReNeuron Group
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 BioRestorative Therapies
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 DiscGenics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us